Skip to main content

Table 1 Description of 1584 subjects with COPD according to GOLD 2011 Classification (frequency of each variable by COPD severity)

From: Comorbidities and COPD severity in a clinic-based cohort

 

A N = 435

B

N = 391

C

N = 178

D

N = 580

p

Males, %

68.5

62.6

62.9

64.6

0.3006

Age, yr (SD)

63.2(10.4)

69(10.8)

63.6(10.6)

68.2(11)

0.0006

BMI, (kg/m2), % < 21

    

0.0001

(underweight) [21–26[(normal)

12.4

13.3

21.3

19.6

 

[26–29[(overweight)

37.7

30.2

33.2

36.4

 

> 29 (obese)

21.8

21.2

22.5

17.6

 

28.3

35.3

23

26.4

 

FEV1, % pred

    

0.0001

> 80%

109(25)

55(14)

26(14.6)

13(2.2)

 

50–80%

326(75)

336(86)

62(34.9)

141(24.3)

 

30–50%

85(47.8)

328(56.5)

 

< 30%

5(2.8)

98(16.9)

 

mMRC 0–1, n(%)

435(100)

0

178(100)

0

0.0001

mMRC > =2, n(%)

0

391(100)

0

580(100)

0.0001

Chronic cough, n(%)

190(43.6)

222(56.7)

96(53.9)

402(69.3)

< 0.0001

Current smokers, n(%)

170(39.8)

131(34.5)

68(39.5)

195(34.5)

0.2394

0–1 exacerbation previous year, n(%)

435(100)

391(100)

71(40)

231(39.8)

0.0001

> = 2 exacerbations, previous year, n(%)

0

0

107(60)

349(60.2)

0.0001

Pulmonary rehabilitation, n(%)

12(2.7)

23(5.8)

10(5.6)

97(16.7)

< 0.0001

Smoking cessation, n(%)

35(8.0)

23(5.8)

26(14.6)

58(10)

0.0053

SABA, %

28.7

44.2

37

47

< 0.0001

LABA, or LAMA, %

53.1

72.1

66.8

71.2

< 0.0001

ICS and LABA, %

18.1

24.8

24.2

39

< 0.0001

Annual influenza vaccination, n(%)

166(38.1)

230(58.8)

93(52.2)

410(70.6)

< 0.0001

Pneumococcal vaccination, n(%)

141(32.4)

204(52.1)

100(56.1)

379(65.3)

< 0.0001

  1. Abbreviations: SABA short-acting bronchodilators LABA long-acting bronchodilators. LAMA long-acting muscarinic antagonist